Our results indicate that FN14 is the most useful predictive/prognostic biomarker of BrM in breast cancer patients with Luminal (Luminal A, Luminal B, and Luminal/Her2+) carcinomas. This evidence concerns the gene TNFRSF12A and breast carcinoma.